Gold News | CStone Pharmaceuticals (02616) announced that it presented the preclinical data of its pipeline 2.0 heavyweight product CS2009 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC Annual Meeting). CS2009 is a trispecific antibody targeting PD-1, CTLA-4, and VEGFA.

Key highlights: 1) CS2009 is a trispecific antibody targeting PD-1, CTLA-4, and VEGFA. 2) Preclinical data indicates that CS2009 has significantly superior anti-tumor activity compared to potential competitors. 3) CS2009 is expected to cover a wide range of tumor types and become the first-in-class/best-in-class next-generation tumor immunity framework product. 4) CStone Pharmaceuticals plans to submit the Investigational New Drug (IND) application for CS2009 by the end of 2024 or early 2025, and initiate the first human study in early 2025.

Dr. Yang Jianxin, CEO, President of R&D, and Executive Director of CStone Pharmaceuticals, stated: "As a key product in CStone Pharmaceuticals' pipeline 2.0, CS2009 has the potential to be a first-in-class/best-in-class next-generation tumor immunity framework product, expected to substitute existing PD-(L)1 therapies. The excellent preclinical data for CS2009 further enhances the confidence in subsequent clinical development. The company looks forward to seeing CS2009 benefit patients, including those with non-small cell lung cancer, ovarian cancer, renal cell carcinoma, cervical cancer, hepatocellular carcinoma, and gastric cancer, especially those with low PD-L1 expression or PD-L1 negative populations who do not respond well to PD-(L)1 therapies."